In the summer of 2019, a 34-year-old woman from Forest, Mississippi, became the first person in the United States to receive a CRISPR-based gene therapy. Her name is Victoria Gray, and she had lived her entire life with sickle cell disease -- a painful, debilitating genetic condition that affects roughly 100,000 Americans and millions of people worldwide, predominantly of African descent. What happened to Victoria after that treatment has become one of the most powerful stories in modern medicine: a story of suffering, courage, scientific triumph, and the promise that gene editing can cure diseases that have tormented humanity for centuries.
A Life Defined by Pain
Sickle cell disease is caused by a single mutation in the gene encoding beta-globin, a protein component of hemoglobin -- the molecule in red blood cells that carries oxygen throughout the body. The mutation causes hemoglobin molecules to clump together under low-oxygen conditions, distorting red blood cells into rigid, crescent-shaped "sickles." These misshapen cells clog blood vessels, blocking oxygen delivery and triggering episodes of excruciating pain known as vaso-occlusive crises.
Victoria Gray experienced her first pain crisis as a baby. Throughout her childhood and adult life, she endured regular episodes that sent her to the emergency room, sometimes lasting days. The crises could strike without warning -- triggered by cold weather, dehydration, stress, or simply by the random hemodynamics of her circulatory system. Between crises, she suffered from chronic fatigue, anemia, and organ damage. She required frequent blood transfusions, which carried their own risks of infection and iron overload.
By her thirties, Victoria was a mother of four who had spent more time in hospitals than she could count. She had undergone surgeries, endured countless needle sticks, and lived with the constant knowledge that sickle cell disease shortens life expectancy significantly. The median life expectancy for Americans with sickle cell disease is approximately 45 years, far below the national average.
Volunteering for the Unknown
In 2019, Victoria learned about a clinical trial being conducted by Vertex Pharmaceuticals and CRISPR Therapeutics at the Sarah Cannon Research Institute in Nashville, Tennessee. The trial, known as CTX001 (later renamed Casgevy), was testing whether CRISPR-Cas9 gene editing could cure sickle cell disease by modifying a patient's own blood stem cells.
The approach was ingenious in its logic. Rather than trying to fix the sickle cell mutation directly, the treatment targeted a different gene: BCL11A, a repressor that silences fetal hemoglobin production after birth. During fetal development, humans produce a form of hemoglobin (fetal hemoglobin, or HbF) that does not sickle. After birth, a genetic switch turns off fetal hemoglobin and turns on adult hemoglobin -- which, in sickle cell patients, is the defective version. By using CRISPR to disrupt BCL11A in blood stem cells, the therapy aimed to reawaken fetal hemoglobin production, effectively providing a functional substitute for the defective adult hemoglobin.
Victoria understood the risks. No human had ever been treated this way before in the United States. The therapy required a grueling process: extracting her own bone marrow stem cells, editing them in a laboratory, then destroying her existing bone marrow with high-dose chemotherapy before reinfusing the edited cells. If the edited cells failed to engraft, she could die. But Victoria decided the chance of a cure outweighed the risks. "I was willing to do whatever it took," she later told reporters.
The Treatment Process
The treatment unfolded in several stages over the course of months. First, Victoria received injections of a drug called plerixafor combined with a growth factor to mobilize her blood stem cells from the bone marrow into the bloodstream, where they could be collected through a process called apheresis. The collected cells were shipped to a laboratory where CRISPR-Cas9 was used to edit the BCL11A gene in each stem cell.
While the editing was performed, Victoria underwent myeloablative chemotherapy -- a brutal regimen designed to destroy her existing bone marrow and make room for the edited cells. This was one of the most dangerous parts of the process. Without a functioning bone marrow, Victoria's immune system was essentially eliminated. She was isolated in a hospital room, vulnerable to any infection.
In July 2019, the edited stem cells were reinfused into Victoria's bloodstream through an IV, much like a blood transfusion. The hope was that these cells would migrate to her bone marrow, engraft, and begin producing red blood cells with high levels of fetal hemoglobin.
The Results
The results exceeded expectations. Within months, Victoria's fetal hemoglobin levels rose dramatically. Before treatment, her fetal hemoglobin was negligible -- as is typical for adults. After treatment, fetal hemoglobin constituted roughly half of her total hemoglobin, far above the threshold needed to prevent sickling.
More importantly, Victoria stopped having pain crises. For the first time in her life, she went months -- then years -- without the agonizing episodes that had defined her existence. She no longer needed blood transfusions. She could play with her children, work, and live a normal life.
"I am living proof that miracles still happen," Victoria told NPR's Rob Stein, who had been documenting her journey from the beginning in a series of reports that brought her story to millions of listeners.
Testifying Before the Senate
Victoria's transformation made her not only a medical success story but also an advocate. In 2023, she testified before the United States Senate, describing her experience with sickle cell disease and her treatment with CRISPR. Her testimony was a powerful argument for the potential of gene therapy and for equitable access to these new treatments.
She spoke about the decades of neglect that sickle cell disease had endured compared to other genetic conditions. Despite affecting a similar number of Americans as cystic fibrosis, sickle cell disease has historically received a fraction of the research funding -- a disparity widely attributed to the fact that sickle cell disproportionately affects Black Americans. Victoria's advocacy helped draw attention to this inequity and to the broader question of who will be able to afford transformative gene therapies.
FDA Approval and the Casgevy Milestone
In December 2023, the FDA approved Casgevy (exagamglogene autotemcel) for the treatment of sickle cell disease in patients aged 12 and older with recurrent vaso-occlusive crises. It was the first CRISPR-based therapy to receive FDA approval for any condition -- a milestone that many considered the culmination of a decade of research that began with the 2012 Doudna-Charpentier paper.
The approval was historic, but it also raised urgent questions about access and cost. Casgevy's list price was set at approximately $2.2 million per patient, reflecting the complex, individualized nature of the treatment. For the estimated 100,000 Americans with sickle cell disease -- many of whom rely on Medicaid -- the question of who will pay for and receive this therapy remains unresolved.
What Victoria's Story Means
Victoria Gray's experience represents far more than a single patient's cure. It is a proof of concept for the entire field of CRISPR-based gene therapy. If a genetic disease caused by a single mutation can be effectively cured by editing a patient's own cells, then similar approaches may work for hundreds of other monogenic diseases -- from beta-thalassemia to muscular dystrophy to certain forms of blindness.
Victoria's story also underscores the human dimension of scientific breakthroughs. Behind every clinical trial statistic is a person who made the decision to trust an unproven technology with their life. Victoria's courage, her willingness to be first, and her subsequent advocacy have made her an icon of the gene editing revolution.
Recent Developments (2025–2026)
More than five years after her treatment, Victoria Gray remains completely symptom-free. She has not had a sickle cell crisis or blood transfusion since her 2019 therapy, takes no medication for sickle cell disease, and her blood counts remain stable. Now 37 years old, she works full-time and is an active mother — a dramatic transformation from a life of monthly hospitalizations and constant pain.
Gray has become a powerful advocate for gene therapy access, testifying before Congress and speaking at medical conferences about her experience. In her own words: "I'm not just existing anymore but thriving." Casgevy, the therapy she pioneered, received FDA approval in December 2023 and saw patient initiation increase 3x in 2025, with 64 patients treated that year.
Sources & Further Reading
- Victoria Gray interview, The CRISPR Journal (2024)
- "Meet Victoria Gray," Innovative Genomics Institute
- NPR's ongoing coverage of Victoria Gray's journey
- FDA approval announcement, December 8, 2023
For the millions of people around the world living with sickle cell disease, Victoria Gray's story offers something that has been scarce for far too long: genuine hope.
